On April 28, 2022 Seagen Inc. (Nasdaq:SGEN) reported upcoming presentations of new data from its expanding pipeline of marketed and investigational therapies at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, to be held June 3-7, 2022 in Chicago (Press release, Seagen, APR 28, 2022, View Source [SID1234613152]). The accepted abstracts demonstrate the growth of Seagen’s portfolio and clinical progress across multiple cancer types, including cervical and urothelial cancers and pediatric and adult Hodgkin lymphoma. Groundbreaking overall survival data for Stage III/IV Hodgkin lymphoma patients who were treated with ADCETRIS (brentuximab vedotin) as part of a first-line therapy combination will be detailed in one of three oral presentations for the antibody-drug conjugate medicine.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Other important data include interim results from the dose-expansion cohorts of the innovaTV 205 trial of TIVDAK (tisotumab vedotin-tftv) in combination with other anticancer agents in patients with recurrent metastatic cervical cancer, which will also be featured in an oral presentation. Long-term outcomes from the phase 3 EV-301 trial of PADCEV (enfortumab vedotin-ejfv) in patients with previously treated advanced urothelial carcinoma will be shared in a poster discussion.
"Significant improvements in overall and event-free survival are important new findings in adult and pediatric Hodgkin lymphoma patients, respectively," said Roger Dansey, M.D., Chief Medical Officer at Seagen. "We look forward to the presentations and plan to submit supplemental applications to the Food and Drug Administration to update overall survival in the ADCETRIS prescribing information for Hodgkin lymphoma and expand its indication to include children."
Key data presentations for Seagen include:
Presentations of Company-Sponsored Trials
Abstract Title
Abstract #
Presentation
Lead Author
ADCETRIS (brentuximab vedotin)
First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with Stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1
7503
Oral
Friday, June 3
2 p.m. CT
S. M. Ansell
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study
7559
Poster
Saturday, June 4
8 a.m. CT
N. L. Bartlett
Updated safety and efficacy data from an open-label, phase 1/2 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) in pediatric patients with advanced-stage classical Hodgkin lymphoma (cHL)
10000
Oral
Monday, June 6
3 p.m. CT
A. R. Franklin
The impact of classic Hodgkin lymphoma (cHL) on informal caregivers: Results from the cHL: Real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT) study
E24004
Online Publication
D. R. Flora
PADCEV (enfortumab vedotin-ejfv)
Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
4516
Poster Discussion
Saturday, June 4
5:04 p.m. CT
J. E. Rosenberg
Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible
4582
Poster
Saturday, June 4
1:15 p.m. CT
D. P. Petrylak
Benchmarking maintenance therapy survival in first-line advanced urothelial carcinoma using disease modeling
4575
Poster
Saturday, June 4
1:15 p.m. CT
M. D. Galsky
Real world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma
4565
Poster
Saturday, June 4
1:15 p.m. CT
G. P. Sonpavde
TIVDAK (tisotumab vedotin-tftv)
Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
5532
Poster
Saturday, June 4
1:15 p.m. CT
K. Sonawane
Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer
5523
Poster Discussion
Saturday, June 4
4:30 p.m. CT
T. Castellano
Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205
5507
Oral
Monday, June 6
10:12 a.m. CT
D. Lorusso
Productivity losses under various second-line recurrent or metastatic cervical cancer treatment scenarios in the United States
E17520
Online Publication
J. Ting
Patterns of care in Medicaid-enrollees with recurrent or metastatic cervical cancer
E17525
Online Publication
C. A. Leath
TIVDAK (tisotumab vedotin-tftv) Trials in Progress
Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC)
TPS5603
Poster
Saturday, June 4
1:15 p.m. CT
I. Vergote
innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors
TPS6100
Poster
Monday, June 6
1:15 p.m. CT
X. Le
TUKYSA (tucatinib) Trials in Progress
Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)
TPS1108
Poster
Monday, June 6
8 a.m. CT
E. P. Hamilton
Phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress)
TPS1111
Poster
Monday, June 6
8 a.m. CT
I. E. Krop
Disitamab vedotin
Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma
4518
Poster Discussion
Saturday, June 4
5:26 p.m. CT
X. Sheng
A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma
4519
Poster Discussion
Saturday, June 4
5:26 p.m. CT
H. Xu
RC48-ADC for metastatic urothelial carcinoma with HER2 -positive: Combined analysis of RC48-C005 and RC48-C009 trials
4520
Poster Discussion
Saturday, June 4
5:26 p.m. CT
X. Sheng
Pipeline Trials in Progress
Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody–drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V-001, trial in progress)
TPS3155
Poster
Sunday, June 5
8 a.m. CT
A. Patnaik
Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress)
TPS3154
Poster
Sunday, June 5
8 a.m. CT
A. Patnaik
Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody–drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress)
TPS3159
Poster
Sunday, June 5
8 a.m. CT
N. Lakhani
Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
TPS1127
Poster
Monday, June 6
8 a.m. CT
J. L. Meisel
Presentations of Investigator-Sponsored or Cooperative Group Trials
Abstract Title
Abstract #
Presentation
Lead Author
Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children’s Oncology Group phase 3 study AHOD1331 (NCT 02166463)
7504
Oral
Friday, June 3
2:12 p.m. CT
S. M. Castellino
Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma
TPS7589
Poster
Saturday, June 4
8 a.m. CT
R. E. Steiner